Specialty Pharma/Generic - Listed on 30 December 2024
Senores Pharmaceuticals (Specialty Pharma/Generic) closed its IPO window in 2024 and listed on NSE and BSE on 30 December 2024 at an upper band issue price of Rs 391, opening at Rs 600 for a listing gain of +53.5% and closing day one at Rs 557.05 (+42.5% on closing basis). The IPO was subscribed 93.41x overall - QIB 94.66x, HNI/NII 96.11x, Retail 89.22x. The total issue size was Rs 582.11 Cr (Fresh Issue Rs 500 Cr, OFS Rs 82.11 Cr). IPO GMP data, subscription trends across Day 1 - Day 3 and Nifty performance around the listing window are detailed below.
Specialty Pharma/Generic
Senores Pharmaceuticals operates in the Specialty Pharma/Generic space. The company’s listed profile is shaped by its operating niche, customer demand and ability to convert that demand into steady cash flows. Investors should read its exchange filings alongside the headline listing numbers for a fuller view of the business.
Issue structure, listing outcome and context
The Senores Pharmaceuticals issue was offered at an upper price of Rs 391 and raised approximately Rs 582.11 crore. The final outcome reflected a mix of subscription demand, valuation, market conditions and the company’s own operating story. Fresh issue and offer-for-sale details, where available, are shown in the issue metrics below.
Number of times each investor category subscribed by close of Day 3.
How overall subscription built up across the three-day issue window.
Grey market premium (GMP) tracked day-by-day across the IPO window. Absolute GMP is the premium in rupees over the upper issue price; GMP % is that premium as a percent of the issue price.
| Day | GMP (Rs) | GMP % |
|---|---|---|
| Day 1 | Rs 150 | +63.94% |
| Day 2 | Rs 150 | +61.38% |
| Day 3 | Rs 150 | +61.38% |
| Day 4 | Rs 175 | +56.78% |
| Day 5 | Rs 222 | +56.78% |
Comparison between market-based GMP prediction and IPOGyani's AI-powered listing gain prediction.
How the broader market moved around the Senores Pharmaceuticals IPO window. Helpful for isolating how much of the listing gain came from company fundamentals vs. market tailwind.
Senores Pharmaceuticals IPO listed at +53.5% versus the upper issue price of Rs 391 on 30 December 2024.
Senores Pharmaceuticals IPO was subscribed 93.41x overall. QIB portion was subscribed 94.66x, HNI / NII 96.11x and Retail 89.22x.
IPO GMP started at Rs 150 on Day 1 and moved to Rs 222 by the close of the issue window. See the day-by-day GMP table above for the full trajectory.